CN1844096A - 一种米格列奈钙的制备及质量控制方法 - Google Patents
一种米格列奈钙的制备及质量控制方法 Download PDFInfo
- Publication number
- CN1844096A CN1844096A CN 200610011970 CN200610011970A CN1844096A CN 1844096 A CN1844096 A CN 1844096A CN 200610011970 CN200610011970 CN 200610011970 CN 200610011970 A CN200610011970 A CN 200610011970A CN 1844096 A CN1844096 A CN 1844096A
- Authority
- CN
- China
- Prior art keywords
- solution
- adds
- product
- methyl alcohol
- synthesizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PMRVFZXOCRHXFE-FMEJWYFOSA-L Kad 1229 Chemical compound [Ca+2].C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1.C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1 PMRVFZXOCRHXFE-FMEJWYFOSA-L 0.000 title claims abstract description 64
- 229960003365 mitiglinide Drugs 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000003908 quality control method Methods 0.000 title abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 24
- 239000001257 hydrogen Substances 0.000 claims abstract description 24
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 19
- GTOFKXZQQDSVFH-VIFPVBQESA-N (r)-2-benzylsuccinate Chemical compound OC(=O)C[C@@H](C(O)=O)CC1=CC=CC=C1 GTOFKXZQQDSVFH-VIFPVBQESA-N 0.000 claims abstract description 15
- 235000019260 propionic acid Nutrition 0.000 claims abstract description 11
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims abstract description 9
- GTOFKXZQQDSVFH-UHFFFAOYSA-N 2-benzylsuccinic acid Chemical compound OC(=O)CC(C(O)=O)CC1=CC=CC=C1 GTOFKXZQQDSVFH-UHFFFAOYSA-N 0.000 claims abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 105
- 239000000243 solution Substances 0.000 claims description 86
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
- 239000000047 product Substances 0.000 claims description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 40
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 34
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 30
- 230000002194 synthesizing effect Effects 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 22
- 238000012360 testing method Methods 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 239000012071 phase Substances 0.000 claims description 17
- 229960004756 ethanol Drugs 0.000 claims description 15
- 239000012141 concentrate Substances 0.000 claims description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 238000003556 assay Methods 0.000 claims description 12
- 239000010410 layer Substances 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 10
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 8
- 230000003287 optical effect Effects 0.000 claims description 8
- 239000012044 organic layer Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000012043 crude product Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 238000007689 inspection Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 239000013558 reference substance Substances 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 4
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- -1 filter Substances 0.000 claims description 3
- 150000002466 imines Chemical class 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 2
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000005660 chlorination reaction Methods 0.000 claims description 2
- 238000006114 decarboxylation reaction Methods 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- IOLQWGVDEFWYNP-UHFFFAOYSA-N ethyl 2-bromo-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)Br IOLQWGVDEFWYNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000010812 external standard method Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000005194 fractionation Methods 0.000 claims description 2
- 239000012362 glacial acetic acid Substances 0.000 claims description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000009965 odorless effect Effects 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000003822 preparative gas chromatography Methods 0.000 claims description 2
- 239000010453 quartz Substances 0.000 claims description 2
- 230000000630 rising effect Effects 0.000 claims description 2
- 238000004062 sedimentation Methods 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 238000002798 spectrophotometry method Methods 0.000 claims description 2
- 238000011003 system suitability test Methods 0.000 claims description 2
- 239000012085 test solution Substances 0.000 claims description 2
- 238000010792 warming Methods 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 8
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 abstract 1
- 150000003949 imides Chemical class 0.000 abstract 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000003914 insulin secretion Effects 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- ARLZGEXVMUDUQZ-UHFFFAOYSA-N O.O.[Ca] Chemical compound O.O.[Ca] ARLZGEXVMUDUQZ-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 208000031662 Noncommunicable disease Diseases 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010060766 Heteroplasia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100119707A CN100441570C (zh) | 2006-05-24 | 2006-05-24 | 一种米格列奈钙的制备及质量控制方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100119707A CN100441570C (zh) | 2006-05-24 | 2006-05-24 | 一种米格列奈钙的制备及质量控制方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1844096A true CN1844096A (zh) | 2006-10-11 |
CN100441570C CN100441570C (zh) | 2008-12-10 |
Family
ID=37063067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100119707A Expired - Fee Related CN100441570C (zh) | 2006-05-24 | 2006-05-24 | 一种米格列奈钙的制备及质量控制方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100441570C (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102101838A (zh) * | 2010-12-06 | 2011-06-22 | 张家港田由新材料科技有限公司 | 一种米格列奈钙的制备方法 |
CN102659562A (zh) * | 2012-05-09 | 2012-09-12 | 山东铂源药业有限公司 | 一种米格列奈钙中间体的合成方法 |
CN102659561A (zh) * | 2012-05-09 | 2012-09-12 | 山东铂源药业有限公司 | 一种s-苄基琥珀酸的制备方法 |
CN103709092A (zh) * | 2013-11-04 | 2014-04-09 | 河北科技大学 | 高纯度米格列奈钙的制备方法 |
CN103864669A (zh) * | 2012-12-14 | 2014-06-18 | 南京长澳医药科技有限公司 | 一种米格列奈钙的新晶型及其制备方法 |
CN104387277A (zh) * | 2014-11-11 | 2015-03-04 | 常州大学 | 一种2-硝基-3-苯基苯丙酮的合成方法 |
CN108409632A (zh) * | 2018-05-28 | 2018-08-17 | 仪征市海帆化工有限公司 | 一种顺式1,2,3,6-四氢邻苯二甲酰亚胺的合成方法 |
CN108689910A (zh) * | 2018-05-18 | 2018-10-23 | 仪征市海帆化工有限公司 | 一种1-环己烯-1,2-二甲酰亚胺的合成方法 |
CN108982706A (zh) * | 2018-09-14 | 2018-12-11 | 山东铂源药业有限公司 | 一种米格列奈钙中杂质顺式全氢异吲哚的检测方法 |
CN109580821A (zh) * | 2018-12-21 | 2019-04-05 | 山东铂源药业有限公司 | 一种s-苄基琥珀酸中杂质丁二酸的检测方法 |
CN110568100A (zh) * | 2019-09-12 | 2019-12-13 | 江西济民可信金水宝制药有限公司 | 一种米格列奈钙r-异构体的检测方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998032727A1 (fr) * | 1997-01-24 | 1998-07-30 | Kissei Pharmaceutical Co., Ltd. | Procede de production d'un acide benzylsuccinique optiquement actif et de substances intermediaires dudit acide |
FR2805535B1 (fr) * | 2000-02-25 | 2002-04-12 | Adir | Nouveau procede de preparation de l'isoindoline |
JP2004131399A (ja) * | 2002-10-08 | 2004-04-30 | Ihara Chem Ind Co Ltd | シス−ヘキサヒドロイソインドリンの製造法 |
FR2860231B1 (fr) * | 2003-09-25 | 2005-11-18 | Servier Lab | Nouveau procede de preparation du cis-octahydro-isoindole |
FR2860230B1 (fr) * | 2003-09-25 | 2006-01-21 | Servier Lab | Nouveau procede de preparation du cis-octahydro-isoindole |
CN100506794C (zh) * | 2003-11-13 | 2009-07-01 | 中国科学院上海药物研究所 | 一种制备抗糖尿病药物米格列奈的新方法 |
CN1324010C (zh) * | 2005-01-12 | 2007-07-04 | 江苏省药物研究所 | 一种米格列奈的制备方法 |
-
2006
- 2006-05-24 CN CNB2006100119707A patent/CN100441570C/zh not_active Expired - Fee Related
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102101838B (zh) * | 2010-12-06 | 2012-09-12 | 周玉莲 | 一种米格列奈钙的制备方法 |
CN102101838A (zh) * | 2010-12-06 | 2011-06-22 | 张家港田由新材料科技有限公司 | 一种米格列奈钙的制备方法 |
CN102659562A (zh) * | 2012-05-09 | 2012-09-12 | 山东铂源药业有限公司 | 一种米格列奈钙中间体的合成方法 |
CN102659561A (zh) * | 2012-05-09 | 2012-09-12 | 山东铂源药业有限公司 | 一种s-苄基琥珀酸的制备方法 |
CN103864669A (zh) * | 2012-12-14 | 2014-06-18 | 南京长澳医药科技有限公司 | 一种米格列奈钙的新晶型及其制备方法 |
CN103709092A (zh) * | 2013-11-04 | 2014-04-09 | 河北科技大学 | 高纯度米格列奈钙的制备方法 |
CN103709092B (zh) * | 2013-11-04 | 2016-07-06 | 河北科技大学 | 米格列奈钙的制备方法 |
CN104387277A (zh) * | 2014-11-11 | 2015-03-04 | 常州大学 | 一种2-硝基-3-苯基苯丙酮的合成方法 |
CN108689910B (zh) * | 2018-05-18 | 2022-04-12 | 仪征市海帆化工有限公司 | 一种1-环己烯-1,2-二甲酰亚胺的合成方法 |
CN108689910A (zh) * | 2018-05-18 | 2018-10-23 | 仪征市海帆化工有限公司 | 一种1-环己烯-1,2-二甲酰亚胺的合成方法 |
CN108409632A (zh) * | 2018-05-28 | 2018-08-17 | 仪征市海帆化工有限公司 | 一种顺式1,2,3,6-四氢邻苯二甲酰亚胺的合成方法 |
CN108982706B (zh) * | 2018-09-14 | 2021-03-02 | 山东铂源药业有限公司 | 一种米格列奈钙中杂质顺式全氢异吲哚的检测方法 |
CN108982706A (zh) * | 2018-09-14 | 2018-12-11 | 山东铂源药业有限公司 | 一种米格列奈钙中杂质顺式全氢异吲哚的检测方法 |
CN109580821A (zh) * | 2018-12-21 | 2019-04-05 | 山东铂源药业有限公司 | 一种s-苄基琥珀酸中杂质丁二酸的检测方法 |
CN109580821B (zh) * | 2018-12-21 | 2021-03-19 | 山东铂源药业有限公司 | 一种s-苄基琥珀酸中杂质丁二酸的检测方法 |
CN110568100A (zh) * | 2019-09-12 | 2019-12-13 | 江西济民可信金水宝制药有限公司 | 一种米格列奈钙r-异构体的检测方法 |
CN110568100B (zh) * | 2019-09-12 | 2022-05-31 | 江西金水宝制药有限公司 | 一种米格列奈钙r-异构体的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100441570C (zh) | 2008-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1844096A (zh) | 一种米格列奈钙的制备及质量控制方法 | |
DE69109291T2 (de) | Oxazolidindione als hypoglykämische und hypocholesterolämische Wirkstoffe. | |
CN1212622A (zh) | 应用PPARα或PPARγ拮抗剂治疗X综合征 | |
JP2009532328A (ja) | 5−ht1b受容体の放射性リガンド | |
CN110200955A (zh) | 四氢异-α酸衍生物、组合物及方法 | |
CN1646490A (zh) | 新的阿托韦兹他汀半钙结晶以及制备它们的方法,以及新的制备阿托韦兹他汀半钙形式ⅰ,ⅷ和ⅸ的方法 | |
US20140271474A1 (en) | Inhibitor probes for imaging sodium-glucose cotransporters in health and disease | |
CN112638873A (zh) | 吲哚菁绿的精制方法 | |
CN112552272A (zh) | 香豆素类化合物及其制备方法和应用、药物组合物 | |
CN113024657A (zh) | 靶向胰高血糖素样肽-1受体的exendin-4放射性探针及其制备方法 | |
CN108047145B (zh) | 与Tau蛋白具有亲和力的2-芳基喹喔啉类化合物及其制备方法与应用 | |
CN113402458B (zh) | 一种恩诺沙星共晶及其制备方法 | |
CN114075167B (zh) | 靶向转位蛋白tspo的新型正电子药物[18f]tpo1开发 | |
CN108017614A (zh) | Dpp-4抑制剂及其在制备治疗2型糖尿病药物中的应用 | |
CN115925650B (zh) | 一种依帕司他共晶及其制备方法和应用 | |
WO2012016419A1 (zh) | Glp-1衍生物及其应用 | |
CN107162913B (zh) | 一类新型氘代苯丙酸衍生物、其制备方法及其作为药物的用途 | |
CN107235842B (zh) | 一种苯丙酸酯衍生物及其制备方法和应用 | |
CN1395555A (zh) | 二羧酸醚钙、其制备方法、和用其治疗血管疾病和糖尿病的方法 | |
CN1023646C (zh) | 原儿茶醛糖类衍生物的制备方法 | |
CN1236779A (zh) | 雷尼替丁枸橼酸铋盐的制备方法 | |
CN114957293B (zh) | 用于特异性识别胰岛素的基于鸟嘌呤的花菁探针及其制备方法 | |
CN107868032A (zh) | 一种取代的苯基丙酸化合物对映异构体及其制备方法、组合物和应用 | |
CN102659772B (zh) | 一种与Aβ斑块有亲和力的2-芳基苯并杂环化合物及其制备方法和应用 | |
CN1443186A (zh) | 用于糖尿病治疗的噻唑烷二酮盐 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO., Free format text: FORMER OWNER: YAN JIE Effective date: 20111018 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300203 HEXI, TIANJIN TO: 300000 HEXI, TIANJIN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20111018 Address after: 300000, Tianjin Dagu South Road, respect 4, 3, Hexi District Patentee after: Tianjin Sino Pharmaceutical Biotechnology Co., Ltd. Address before: 300203, Tianjin Dagu South Road, respect 4, 3, Hexi District Patentee before: Yan Jie |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081210 Termination date: 20160524 |
|
CF01 | Termination of patent right due to non-payment of annual fee |